Fosun Pharma’s H1 Profit Leaps 144 Percent

Fosun Pharma has reported that its gross profit reached RMB 631 million while net profit attributable to shareholders of its parent company hit RMB 496 million in the first half of 2008, up 145 percent and 144 percent respectively over the same periods last year. The huge jump results from rapid expansion of its drug R&D, pharmaceutical business, and investment in high-performing Sinopharm Medicine Holding. Fosun's pharmaceutical R&D core enterprises such as Newsummit Biopharma, Chongqing Yaoyou Pharmaceuticals and Wanbang Biopharma all achieved impressive growth rates greatly exceeding the industry average. Fosun's key products - antimalarial drug Co-Artesun, insulin drug Glimepiride and liver-care drug Atuomolan - continue to maintain leading positions in their individual market segments. (Click here for more - Chinese Language)